Last Update 10 Mar 26

Fair value Decreased 2.20%

BIM: Food Diagnostics Expansion And Higher Margins Will Support Future Returns

Narrative Update

Analysts have trimmed their fair value estimate for bioMérieux to €116.50 from €119.12, reflecting lower Street price targets along with updated assumptions for revenue growth, margins and future P/E multiples.

Analyst Commentary

Recent research updates point to a more cautious stance on bioMérieux, with several firms trimming price targets and one downgrade. Here is how analysts are framing the risk and reward right now.

Bullish Takeaways

Bullish analysts who keep neutral style ratings despite lower price targets suggest they still see a case for fair value near current levels, even if upside looks more limited.
The clustering of price targets around €100 and above indicates that, while expectations have been reset, the stock is still being valued as a going concern with meaningful earnings power rather than a distressed situation.
Maintaining rating levels while cutting targets hints that analysts see the recent reassessment as a recalibration of assumptions on growth, margins and P/E rather than a thesis break.

Bearish Takeaways

Lower Street price targets, including moves from around €110 to €100 and a separate €3 cut, point to reduced confidence in the previous valuation framework, especially around revenue growth and margin assumptions.
The downgrade by more cautious analysts signals rising concern around execution risk, with questions about how reliably the company can deliver on its prior growth and profitability expectations.
Target cuts tied to updated P/E assumptions suggest some analysts now see less support for higher multiples, which can cap potential re rating if earnings do not materially surprise to the upside.
The broad reset in targets feeds into the trimmed fair value estimate of €116.50, reinforcing the idea that the balance of risks has shifted and that investors may want to factor in a wider range of potential outcomes for growth and margins.

What's in the News

bioMérieux announced the launch of SMARTBIOME, a solution that uses high precision DNA sequencing, bioinformatics and the company’s microbiology expertise to help food manufacturers identify and prevent microbiological spoilage across production stages, with availability in North America, Latin America and Europe (Key Developments).
SMARTBIOME is built on the spoilage knowledge base and consulting support developed with Neoprospecta, a Brazil based genomics and data science company that bioMérieux acquired in January 2025. The solution aims to turn complex microbiological data into actionable insights for food producers (Key Developments).
The company announced an annual dividend of €0.9800 per share, with an ex date on June 9, 2026, a record date on June 10, 2026, and payment scheduled for June 11, 2026 (Key Developments).
A Special or Extraordinary Shareholders Meeting is scheduled for May 28, 2026 at 376 chemin de l orme, Marcy l Etoile, France, providing investors with a formal forum to follow upcoming corporate decisions (Key Developments).

Valuation Changes

Fair Value was trimmed from €119.12 to €116.50, indicating a small reduction in the central valuation estimate.
The Discount Rate was nudged up slightly from 7.17% to 7.18%, implying a marginally higher required return in the model.
Revenue Growth was lifted from 4.83% to 6.20%, reflecting a higher projected top line expansion rate in the updated assumptions.
The Net Profit Margin was adjusted up from 13.76% to 14.26%, pointing to a modestly stronger expected profitability level.
The Future P/E was reduced from 26.48x to 23.74x, showing a lower valuation multiple being applied to projected earnings.

0 views

Key Takeaways

Strong cross-selling and innovation strategies are driving revenue growth and expanding market leadership in panel and instrument installations.
Profitability improvements through automation and R&D investment are enhancing margins and supporting sustainable long-term growth.
Volatility in BIOFIRE contracts, U.S. market reliance, and competitive pricing pressures could threaten bioMérieux's revenue growth and profitability amid regulatory and currency challenges.

Catalysts

About bioMérieux

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

Strong cross-selling strategy in BIOFIRE nonrespiratory panels, increasing customer engagement and potentially driving revenue growth through more comprehensive panel usage.
SPOTFIRE's exceeded sales guidance and strong adoption in the market indicate robust future revenue growth, contributing to the company's financial performance.
Continuous innovation, including new panel approvals and market leadership in instrument installations, supports sustainable revenue growth and market expansion over the long term.
GO.Simple profitability improvement initiatives, including automation and cost management, are already delivering tangible outcomes, likely enhancing net margins and earnings over time.
Investment in research and development, with 12% of sales reinvested, is aimed at sustaining future growth and maximizing returns, expected to positively impact revenue and potentially improve net margins through high-margin innovative products.

bioMérieux Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming bioMérieux's revenue will grow by 7.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 10.9% today to 13.3% in 3 years time.
Analysts expect earnings to reach €648.5 million (and earnings per share of €5.54) by about September 2028, up from €432.2 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 27.1x on those 2028 earnings, down from 32.2x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 47.0x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.82%, as per the Simply Wall St company report.

bioMérieux Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The volatility in BIOFIRE placements and the impending expiration of 5-year contracts signed during the pandemic could potentially lead to a decline in new installations, affecting future revenue growth.
The potential for increasing competition, particularly from new entries in the U.S. respiratory market such as Diasorin, poses pricing pressure on bioMérieux's core syndromic testing business, potentially impacting net margins.
The significant reliance on the U.S. market means that any regulatory challenges, such as changes in U.S. tariffs or cuts to NIH funding, could materially affect the company's revenue and overall profitability, given that 85% of their products are manufactured in the U.S.
The macroeconomic environment and currency fluctuations present a foreign exchange headwind forecasted at around €30 million for 2025, which could directly impact earnings by reducing the profitability of sales outside the U.S.
While SPOTFIRE's performance appears strong, the intricate U.S. market dynamics and reimbursement variations mean the company could experience slower-than-anticipated growth due to potential future competition, impacting revenue projections and necessary strategic investments.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €123.464 for bioMérieux based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €135.0, and the most bearish reporting a price target of just €90.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €4.9 billion, earnings will come to €648.5 million, and it would be trading on a PE ratio of 27.1x, assuming you use a discount rate of 6.8%.
Given the current share price of €117.9, the analyst price target of €123.46 is 4.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on bioMérieux?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Continued Innovation And Market Leadership Will Ensure Future Success